Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Sanofi SNY reported second-quarter 2025 adjusted earnings of 90 cents per American depositary share, which missed the Zacks ...

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential ...

But Sanofi isn’t only counting on Dupixent for growth. Vaccines are another key piece of the company’s strategy, and those products pulled in €1 billion for the quarter, a 16% increase.

Sanofi reports strong Q2 2025 growth with innovative launches like Dupixent and strategic acquisitions boosting sales.

Sanofi and Regeneron, which co-sell the drug, spent a massive $287.6 million on Dupixent ads last year, making them the highest of all pharma drug spenders in 2021.